New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
08:10 EDTRCPTReceptos risk/reward attractive following data, says Leerink
Leerink believes the Phase II data for RPC-1063 suggests the drug is meaningfully differentiated from other therapies in development at least for patients with relapsing forms of multiple sclerosis. The firm reiterates an Outperform rating on shares of Receptos with a $75 price target and views the risk/reward as attractive.
News For RCPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
16:03 EDTRCPTCelgene completes acquisition of Receptos
Subscribe for More Information
10:19 EDTRCPTOptions with decreasing implied volatility
Subscribe for More Information
August 26, 2015
10:00 EDTRCPTOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:02 EDTRCPTReceptos downgraded to Neutral from Outperform at Wedbush
Subscribe for More Information
August 25, 2015
07:31 EDTRCPTCelgene announces expiration of tender offer for Receptos shares
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use